Moneycontrol PRO
Loans
Loans
HomeNewsBusinessStartupSteady supply of medicines: This startup has a plan in place to get around lockdown restrictions

Steady supply of medicines: This startup has a plan in place to get around lockdown restrictions

Kolkata-based startup uses 178 data sources to offer location based business insights to clients.

April 22, 2020 / 18:53 IST

A Kolkata-based early stage startup Datasutram is looking to solve the problem of availability of products during this uncertain period by using multiple data sources and running its analytics engines to predict demand.

Started by three Jadavpur University engineering graduates - Aisik Paul, Ankit Das and Rajit Bhattacharya - the startup has worked with around 10 pharma companies to ensure a steady supply of medicines across Mumbai, Pune and Kolkata. They are also in talks with more than 20 other companies to help them predict demand and initiate supply.

“We were developing predictive models based on more than 178 data sources like tracking thermal patterns, heat data to show concentration of consumers to identify commercial areas in cities which can be targeted by businesses for their own expansion, We have utilised those same models to help bridge demand supply gap for medicines during these extraordinary times," said Bhattacharya.

For data sources they rely on satellite data, private data sources, government data, Google among many others.

COVID-19 has provided as opportunity for Datasutram to showcase the utility of their analytics engines. The founders claim they have managed to increase deliveries by more than 30 percent for some of their clients. Among products they facilitated are hand sanitisers, medicines, essentials, among others.

COVID-19 Vaccine

Frequently Asked Questions

View more
How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.

View more
Show

Track this blog for latest updates on the coronavirus outbreak

Bhattacharya said these models help predict demand and also give confidence to the consumer that essential products will be available. It can stop panic buying. While they have done it for pharma companies, they are looking to replicate it for grocery: another sector hit by demand and supply mismatch because of the pandemic. They have held conversations with multiple online grocers as well.

"The idea for us is to remain sector agnostic, we can create location centric structured data sets which can be used in multiple ways from government programmes to business insights," said Bhattacharya.

Being part of Sanjay Mehta's 100X VC's first cohort of 20 companies, Datasutram is in talks with angel investors to close a round of funding in the range of Rs 1.5 crore to 2 crore soon.

Follow our full coverage of the coronavirus outbreak here

Invite your friends and family to sign up for MC Tech 3, our daily newsletter that breaks down the biggest tech and startup stories of the day

Pratik Bhakta
first published: Apr 22, 2020 06:31 pm

Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!

Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347